full spectrum cell analysis®
eBioscience®

Anti-Human LAP Functional Grade Purified

Catalog Number: 16-9823
Also Known As:latency-associated peptide, LAP-TGFb
RUO: For Research Use Only. Not for use in diagnostic procedures.



Immunoblot analysis of lysate from normal human platelets run on SDS-PAGE under reducing conditions. The membrane was probed with 5 µg/ml Anti-Human LAP (VB3A9) followed by Anti-Mouse IgG HRP.

Product Information

Contents: Anti-Human LAP Functional Grade Purified
REF **Catalog Number:** 16-9823
Clone: VB3A9
Concentration: 1 mg/mL
Host/Isotype: Mouse IgG1
Handling Conditions: Use in sterile environment.
Endotoxin Level: Less than 0.001 ng/ug antibody, as determined by the LAL assay.

Formulation: aqueous buffer, no sodium azide
Temperature Limitation: Store at 2-8°C.
LOT **Batch Code:** Refer to Vial
Use By: Refer to Vial

Description

This VB3A9 monoclonal antibody recognizes human latency-associated peptide (LAP), also known as the TGF-β propeptide. Human LAP is a homodimer of 65-75 kDa that is non-covalently associated with TGF-β and this complex is also referred to as the small latent complex (SLC). LAP can be covalently associated with latent TGF-β binding proteins (LTBP) through disulfide bonds, forming the large latent complex (LLC). The association of LAP with TGF-β facilitates its secretion and also renders TGF-β inactive.

VB3A9 has been reported to cross-react with non-human primate LAP, but does not cross-react with mouse LAP.

Applications Reported

This VB3A9 antibody has been reported for use in immunoblotting (WB), immunoprecipitation, and immunohistochemical staining.

Applications Tested

This VB3A9 antibody has been tested by immunoblot analysis of human platelets under reducing conditions at 5 µg/ml. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

References

Annes JP, Chen Y, Munger JS, Rifkin DB. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol. 2004 Jun 7;165(5):723-34. (**VB3A9**, WB, Pubmed)

Khalil N. TGF-beta: from latent to active. Microbes Infect. 1999 Dec;1(15):1255-63.

Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999 Feb 5;96(3):319-28. (**VB3A9**, IP, simian, Pubmed).

Gleizes PE, Beavis RC, Mazzieri R, Shen B, Rifkin DB. Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta1. J Biol Chem. 1996 Nov 22;271(47):29891-6.

Related Products

Tel: 888.999.1371 or 858.642.2058 • Fax: 858.642.2046 • www.eBioscience.com • info@eBioscience.com